Sprout Pharmaceuticals

Executive Summary

Sprout Pharmaceuticals, founded in 2011 by Cindy Eckert, is a private biopharmaceutical company dedicated to advancing women's sexual health. Its flagship product, Addyi (flibanserin), was the first FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women, addressing a long-neglected therapeutic gap. Despite initial commercial challenges, including payer coverage and market education, Sprout has steadily improved access and awareness. The company's mission-driven approach, combined with a growing acceptance of female sexual dysfunction as a legitimate medical condition, positions it for potential growth. With an approved product and a focused pipeline, Sprout aims to expand its reach through label extensions, new formulations, or strategic partnerships. The company's private status limits public financial details, but its pioneering role in women's health provides a strong foundation for future catalysts.

Upcoming Catalysts (preview)

• Q3 2026FDA label expansion for Addyi to include postmenopausal women or other indications50% success
• Q4 2026Announcement of strategic partnership or licensing deal for global commercialization60% success
• Q2 2026Publication of real-world evidence or new clinical data supporting Addyi's efficacy and safety70% success